Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Angiopoietin 2/3 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA551083
Description
Angiopoietin 2 + 3 Polyclonal Antibody detects endogenous levels of Angiopoietin 2 + 3 protein.
Angiopoietins are members of the vascular endothelial growth factor family and the only known growth factors largely specific for vascular endothelium. Angiopoietin-1, angiopoietin-2, and angiopoietin-4 participate in the formation of blood vessels. The protein encoded by this gene is another member of the angiopoietin family that is widely expressed in adult tissues with mRNA levels highest in highly vascularized tissues. This protein was found to be a secretory protein that does not act as an endothelial cell mitogen in vitro.
Specifications
Angiopoietin 2/3 | |
Polyclonal | |
Unconjugated | |
ANGPTL2 | |
AI593246; ANG3; ANG-5; angiopoietin 5; angiopoietin like 2; angiopoietin like 3; angiopoietin related protein 2; Angiopoietin-5; angiopoietin-like 2; angiopoietin-like 3; angiopoietin-like protein 2; Angiopoietin-like protein 3; angiopoietin-related protein 2; Angiopoietin-related protein 3; ANGPT3; ANGPT5; Angptl2; Angptl3; ANGPTL3(17-221); ANGPTL3(17-224); ANL3; ARP1; ARP2; AW260363; FHBL2; HARP; hypl; hypolipidemia; UNQ153/PRO179; UNQ170/PRO196 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
171100, 23452, 26360, 27329, 30924, 502970 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
ELISA, Western Blot | |
1 mg/mL | |
PBS with 0.5% BSA, 50% glycerol and 0.02% sodium azide; pH 7.4 | |
Q9R045, Q9R182, Q9UKU9, Q9Y5C1 | |
ANGPTL2, ANGPTL3 | |
Synthesized peptide derived from the Internal region of human Angptl1/2. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction